CORAL GABLES, FL/ ACCESSWIRE / February 22, 2019 / With the new year only a few months old, the biotech stock market is already whirring with the excitement surrounding companies developing nuanced approaches to creating a wide array of new forms of treatment options for patients in need of care. As medical experts discover infectious diseases, the demand for qualitative care solutions becomes exponentially more important. Naturally, companies in the biotech sector working to address these challenges are garnering significant notoriety among consumers as well as investors. Premier Health Group (PHGRF) (PHGI), Ocular Therapeutix Inc (OCUL), Voyager Therapeutics Inc (VYGR), and Amarin Corporation plc (NASDAQ:AMRN) represent 4 biotech stocks stepping up their game on Friday.
Premier Health Group (PHGRF) (PHGI) is a Canadian publicly traded company prepared to meet the growing necessity for cutting-edge drug treatments and healthcare solutions, specifically for patients in the primary care space. Over the last few years, the Company has worked to employ inventive strategies to create a successful and simultaneously effective healthcare framework for its 100,000 active patients. The Company's executive leadership team, comprised of medical experts and health professionals, has an impressive track record of successfully creating value in healthcare and technology enterprises.
Earlier this month, Premier Health Group (PHGRF) (PHGI) provided investors and consumers with a corporate update detailing the Company's successes from the past few months. Premier Health successfully acquired Cloud Practice Inc., a healthcare technology company that provides cloud-based electronic medical records software applications for physicians throughout Canada. Cloud Practice's suite of products includes Juno EMR, a cloud-based EMR solution; ClinicAid, a medical billing software; and MyHealthAccess, an online patient portal.
In recognition of the potential benefits of combining advanced healthcare technologies with alternative forms of treatment, Premier Health Group (PHGRF) (PHGI) will enter the Cannabis clinic space. The role of Cannabis in treating medical conditions is continuously expanding to help patients with acute & chronic symptoms. Currently, there is a critical gap between the patient's need for medical cannabis, and the physician's comfort and knowledge to prescribe it.
Ocular Therapeutix Inc (OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of therapies for diseases and conditions of the eye, announced earlier this week that it has entered into a note purchase agreement with an accredited investor to issue $37.5 million aggregate principal amount of 6.00% subordinated convertible notes due 2026 pursuant to Regulation D promulgated under the Securities Act of 1933, as amended.
Per the details of the offering, Ocular and the purchasers of the notes will enter into a registration rights agreement pursuant to which, among other things, Ocular will agree to prepare and file one or more registration statements with the Securities and Exchange Commission for the purpose of registering for resale the shares issuable upon conversion of the notes.
Voyager Therapeutics Inc (VYGR) made headlines today when the Company announced that it has entered into an exclusive, global strategic collaboration and option agreement to develop and commercialize vectorized antibodies directed at pathological species of alpha-synuclein for the potential treatment of Parkinson's disease and other diseases characterized by the abnormal accumulation of misfolded alpha-synuclein protein with AbbVie.
Andre Turenne, president, and CEO of Voyager said, "our scientific platform allows us to develop unique AAV gene therapies that are designed to knock down disease-causing gene expression, increase the expression of missing proteins, or enable the expression of therapeutic antibodies through vectorization."
Amarin Corporation plc (AMRN) saw impressive gains in mid-afternoon trading on Friday, with its shares soaring 15.26%, trading at $20.09 per share. The Company's market performance could be connected to the fact that they announced earlier this week that a conference call with members of Amarin senior management will be held later this month.
Per the announcement, the purpose of the call will be to discuss the Company's fourth quarter and full year 2018 financial results and provide an operational update. The conference call will follow the anticipated release of the company's financial results earlier that day.
What Is Stock Price (StockPrice.com)?
Stock Price is defined as the price of a single share of a number of saleable stocks of a public company. A stock price is the highest amount an investor or trader is willing to pay for the stock, or the lowest amount that it can be bought for.
StockPrice.com was created for everyone that wants the latest stock quotes, stock charts, company news, and the best financial content.
At Stock Price (StockPrice.com), you get free stock quotes, up-to-date news, international market data, social interaction and the best financial content that will help you manage your financial life.
Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. JSG Communications, LLC which owns www.StockPrice.com is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release.
JSG Communications, LLC, which owns www.StockPrice.com, may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. JSG Communications, LLC, which owns www.StockPrice.com, may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two.
Pursuant to an agreement between MIDAM VENTURES, LLC and Premier Health Group Inc. we were hired for a period from 10/1/2018 - 4/1/2019 to publicly disseminate information about Premier Health Group Inc. including on the Website and other media including Facebook and Twitter. We were paid $300,000 ( CASH) for & were paid "500,000" shares of restricted common shares (as of 1/2/2019). We own zero shares of Premier Health Group Inc., which we purchased in the open market. Once the (6) Six-month restriction is complete on 4/1/2019 we plan to sell the "500,000" shares of Premier Health Group Inc. that we hold currently in restricted form during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of Premier Health Group Inc. in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Please click here for full disclaimer.
View source version on accesswire.com: